Baird Financial Group, Inc. Halozyme Therapeutics, Inc. Transaction History

Baird Financial Group, Inc.

$50.2 Billion
Q3 2024

A detailed history of Baird Financial Group, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 10,898 shares of HALO stock, worth $497,493. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,898

Previous 10,986 0.8%

Holding current value

$497,493

Previous $575,000 8.35%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$51.3 - $64.42 $4,514 - $5,668	-88 Reduced 0.8%	10,898 $623,000
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $3,667 - $5,082	-97 Reduced 0.88%	10,986 $575,000
Q1 2024 May 14, 2024	SELL	$33.68 - $41.95 $3.93 Million - $4.9 Million	-116,715 Reduced 91.33%	11,083 $450,000
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $1.47 Million - $1.85 Million	44,048 Added 52.59%	127,798 $4.72 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $25,193 - $30,424	-691 Reduced 0.82%	83,750 $3.2 Million
Q2 2023 Aug 11, 2023	BUY	$30.28 - $38.74 $276,183 - $353,347	9,121 Added 12.11%	84,441 $3.05 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $76,958 - $130,449	2,342 Added 3.21%	75,320 $2.88 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $54,943 - $73,838	1,426 Added 2.02%	72,114 $2.85 Million
Q2 2022 Aug 08, 2022	BUY	$37.35 - $48.3 $136,925 - $177,067	3,666 Added 5.47%	70,688 $3.11 Million
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $237,057 - $304,459	7,415 Added 12.44%	67,022 $2.67 Million
Q4 2021 Feb 09, 2022	BUY	$31.82 - $40.75 $24,469 - $31,336	769 Added 1.31%	59,607 $2.4 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $593,130 - $715,703	15,418 Added 35.51%	58,838 $2.39 Million
Q2 2021 Aug 11, 2021	BUY	$38.84 - $51.31 $508,687 - $672,007	13,097 Added 43.19%	43,420 $1.97 Million
Q1 2021 May 13, 2021	BUY	$39.51 - $51.45 $293,282 - $381,913	7,423 Added 32.41%	30,323 $1.26 Million
Q4 2020 Feb 11, 2021	BUY	$25.81 - $43.62 $591,049 - $998,897	22,900 New	22,900 $978,000
Q3 2020 Nov 12, 2020	SELL	$25.74 - $29.63 $307,541 - $354,019	-11,948 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $194,155 - $320,325	11,948 New	11,948 $320,000

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.36B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.

Account

Baird Financial Group, Inc. Halozyme Therapeutics, Inc. Transaction History